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RUNNING HEAD: BOOK REVIEW AFTER PLACEBO 
Introduction 
Despite the claim that they are powerful [1] and the growing scientific interest – PubMed lists 31’259 
scientific articles on this topic – Robin Nunn argues that this large and growing body of research has not 
succeeded in providing generally accepted answers to the core question: What exactly is a placebo and is there 
anything that deserves this descriptor?  
Building on his earlier work [2-4], Nunn argues in his book After placebo: In Medical Research and 
Clinical Practice that it is time to abandon the disputed placebo construct. New terms, he argues, are needed to 
replace it in order to better advance medical research and clinical practice alike. While Nunn admits there are 
possible negative consequences (since “not knowing and not being able to explain” placebo effects may be 
uncomfortable” (p.35)) he estimates that science will be expedited as a result of discarding placebo terminology. 
Nunn presents us with a challenging and interesting perspective that invites consideration by both clinicians and 
researchers. But is it warranted? 
Nunn’s criticism of the placebo concept is based on several empirical and theoretical arguments. In the 
introduction, he states that it is not his intention to solve all definitional problems associated with the term 
placebo, but rather to promote the rationale for, and confidence in, abandoning it. The term placebo is depicted 
as a conceptual habit which was useful in the past but which has now lost its purpose and justification. This is 
exemplified in the second chapter, as a parade of dated and more recent placebo definitions is elegantly 
summarized, including the usual suspects from Shapiro and Shapiro [5], Grunbaum [6], Brody [7] and 
Harrington [8]. In the following chapter, the often rather unspectacular reasons underlying often rather 
spectacular cases is illustrated by the case of Mr. Right, who was presumed cured by the intake of a placebo. 
Nunn’s use of the story highlights that the so-called powerful placebo may not be responsible for curing Mr. 
Right. Rather, his experience of clinical change may have been owed to more mundane phenomena such as 
spontaneous remission or regression to the mean. In subsequent chapters, Nunn aptly deconstructs not only the 
semantic absurdity of considering the placebo as something inert, yet at the same time powerful, he also 
describes the challenges of proving its effects in meta-analyses (e.g., Hróbjartsson & Gøtzsche [9]) and surveys 
the responses which argue that these analyses are flawed [10-12]. His tour de force analysis underlines the fact 
that almost any substance can be a placebo, that placebo(-like) effects can even be observed in the absence of the 
administration of placebos, and that placebos can be part of almost any treatment for any condition.  
 So, how does this concept fare in reality? Not surprisingly, Nunn’s verdict is clear: He argues that the 
logic of placebo definitions is circular and reductive. Current “linear models ignore concepts of sensitivity to 
initial conditions, non-linear dynamics, self-reference and feedback […]” (p.65). These problems are seen as the 
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result of the prevailing scientific approach to placebo: he describes it as a “circular logic”, since improvements in 
patients who receive inert treatments are defined as placebo effects, so that observed improvements in patients 
who received inert treatment are then perceived as placebo effects (p.89). These logical problems are not 
eradicated by advocating a linguistic alternative, such as shifting from placebo language to “meaning responses” 
[13] or “context effects” [14]. Nunn argues that these terms are associated with similar conceptual problems and 
leave us with the same challenges: they are, as he puts it, “black boxes within black boxes” (p. 105). He closes 
his critique with the statement that medicine is rife with unexplained symptoms and unexplained cures; he 
concludes that it would be more honest to declare that the reasons, in all these cases, are either unknown or 
poorly understood. According to Nunn, the attempt to elucidate the reasons for symptom alleviation (or indeed, 
worsening) is not advanced by the current approach of so-called blinding, as a significant proportion of 
interventions are too different to be appropriately interchangeable, while others cannot be faked. In conclusion, 
he argues “instead of saying it’s a double-blind experiment with placebo control, say that you are trying to set 
the same beliefs and expectations in everyone while giving them different treatments” (p.138).  
The book moves on to advocate an alternative “After Placebo” era, replete with placebo-free laws, 
guidelines, regulations and medical trainings which, Nunn argues, will offer new implications and opportunities 
for medicine and health. Placebo-free regulations, for example, will not use the term “placebo-controlled study”, 
yet rather describe the purpose of a clinical investigation which “is to compare the safety and effectiveness of a 
drug or procedure with reasonable alternatives appropriate in the circumstances” (p.164). The overarching goal 
is to build a new post-placebo paradigm “so that in future we won’t even see the old structure, as today’s 
medicine does not see the structures of ancient medicine” (p.140). In these sections Nunn develops his earlier 
and tantalizingly brief forays in criticising the placebo concept [2,3]. 
 
All in all, we can agree with Nunn that he is certainly justified in questioning the legitimacy of the 
current placebo construct and makes a strong case for eliminating and replacing that concept with the notion of, 
“an intervention intended to influence the patient’s beliefs, hopes and expectations” (p. 163). Nunn’s point of 
view is refreshingly original in the long, somewhat protracted debate about terminology in placebo studies.  
But one is left wondering: is it really necessary to eradicate the term placebo? A number of omissions in 
Nunn’s book lead to an oversimplified depiction of placebo research. For example, Nunn argues that “we should 
also consider the provider’s expectation and conditioning and the collaboration between patient and provider” 
(p.80). However, this has been done, for example in a recent paper investigating neural correlates of physicians 
during treatment of patients, with the impressive conclusion that physicians activate similar brain regions during 
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the treatment of a patient [15]. Further, Nunn states that placebo theory is dominated by talk of expectation and 
conditioning while “conditioning is conceived as an unconscious process, in contrast to expectation that is 
deemed to be conscious” (p.78). However, other models – such as Bayesian models of perceptual decision – are 
becoming established as an innovative framework in placebo research 16, while recent investigations reveal the 
acquisition of unconscious expectancies [17]. So, in this respect, Nunn has failed to keep abreast of nuanced 
conceptual change within the field. 
Finally, the book highlights some shortcomings of adequate control conditions.  His points on these 
shortcomings are valid though not original, as they have been repeatedly emphasized in placebo research (e.g., 
Blease, Bishop, & Kaptchuk [18]; Howick [19]; Turner [20]) . In addition, some points of criticism on the 
current control conditions may be questionable. For example, Nunn writes that, “[a] waiting list also implies that 
they are waiting for something. The presence of interested experts, the hope, the expectation, the possibility of 
treatment after the waiting period […]” (p. 74). On the contrary, meta-analyses reveal that waiting lists do not 
enhance expectations, but rather induce nocebo effects [21].  
On a more general level, one should keep in mind that the placebo concept also has an ethical 
dimension since in clinical trials, and more troublingly, when administered, in clinical contexts, it typically 
involves deception. Nunn addresses this issue concluding that, “deception in relation to placebo refers only to 
some bending of truth. Deciding where the line is, and adjudicating what is outside the line and what gets in, 
again illustrates the difficulty of dividing the world into placebos and non-placebos” (p. 159). While Nunn 
relativizes deception on the grounds that “no single rule applies for all people in all situations, such as do not lie 
or deceive, do tell the truth, the whole truth and nothing but the truth” (p. 155), his analysis here is unconvincing. 
The overarching duty to inform patients in a transparent manner and to provide truthful disclosure is paramount 
in clinical practice [18]. This is in line with a deontological normative ethical framework, where it is argued that 
deception infringes patient autonomy – regardless of potential health gain [22]. Indeed, we must not lose sight of 
patients’ right to autonomous decision making –even in a post-placebo world. It is important to emphasize that 
this ethical sentiment has been a leitmotif of recent open-label placebo research which advocates the imperative 
of providing adequate information disclosure for patients [23]. On a related point, Nunn urges, “it is curious that 
informing patients about the distinction between deemed active ingredients and inactive placebos matters more 
than information about physicians themselves […] (p. 159)”. Here again, some placebo researchers have bitten 
the bullet and argued that there ought to be disclosure of information about the influence of physicians (and 
indeed other healthcare practitioners) in mediating health outcomes (and placebo effects) [22,24]. 
Nunn’s After Placebo succeeds by stimulating valuable questions and analysis of the current placebo 
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construct – an important, reasonable and necessary undertaking. Nunn’s writing is engaging and evocative, and 
After Placebo is a worthwhile, accessible read suitable for an interdisciplinary healthcare audience. Large 
portions of this work function as a critique of the placebo construct not just in medical research, but also in 
clinical practice. Nevertheless, Nunn’s line of argument might not yet be convincing enough to justify the total 
elimination of placebo terminology. Precisely because the concept of placebo is entrenched in clinical practice, 
and because it is heterogeneous and broadly diversified, it lends itself to interpretation and discussion – thus 
fostering progressive, new insights and findings.  
At the beginning of the book, Nunn states, "I will have achieved my purpose if you [...] are at least 
persuaded that placebo must be considered from more than one viewpoint and that there is no single viewpoint 
that can ever make sense of placebo" (p.7). We can surely agree that he accomplishes this aim.  
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